# A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas

Study · id `cardio:ct-nct04308590` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04308590](<https://clinicaltrials.gov/study/NCT04308590>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04308590

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 137 participants.

## Technical summary

Registry record NCT04308590. Randomized; triple masking; primary purpose treatment. Start 2020-07-27 (actual); primary completion 2024-09-19 (actual). Results posted on 2025-08-03.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 137 participants (enrolled count; ClinicalTrials.gov record NCT04308590, source copy `cardio:ctgov-nct04308590-2025-09-04`, retrieved 2026-10-26)
- Started: 2020-07-27 (actual) (ClinicalTrials.gov record NCT04308590, source copy `cardio:ctgov-nct04308590-2025-09-04`, retrieved 2026-10-26)
- Primary completion: 2024-09-19 (actual) (ClinicalTrials.gov record NCT04308590, source copy `cardio:ctgov-nct04308590-2025-09-04`, retrieved 2026-10-26)
- Completion: 2024-09-19 (actual) (ClinicalTrials.gov record NCT04308590, source copy `cardio:ctgov-nct04308590-2025-09-04`, retrieved 2026-10-26)
- Results first posted: 2025-08-03 (ClinicalTrials.gov record NCT04308590, source copy `cardio:ctgov-nct04308590-2025-09-04`, retrieved 2026-10-26)
- Countries: United States; Austria; Bulgaria; Germany; Israel; Italy; Poland; Romania; Spain (ClinicalTrials.gov record NCT04308590, source copy `cardio:ctgov-nct04308590-2025-09-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04308590-2025-09-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
- Acronym: GRADIENT
- Condition: Hypercortisolism
- Intervention (Drug): Relacorilant
- Intervention (Other): Placebo
- Lead sponsor: Corcept Therapeutics
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Corcept Therapeutics (`cardio:org-corcept-therapeutics`)

## Provenance

Content hash: c7ab0f2b19a1cfed82c19e52c0d0bbecc17fdd3a0f577db7f8b948eb6a5615a2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
